 The study objective is to assess the incidences of major adverse cardiovascular events MACE; defined as a composite of clinically driven target-lesion revascularization, cardiac death, any myocardial infarction, and stent thrombosis at 12-month follow-up, and of stent thrombosis at 1-day, and 1- and 12-month follow-up. Pre-specified analyses will be performed among patient subpopulations according to level of glycemic control HbA1c level 6.5 or 6.5; reference vessel diameter by quantitative coronary angiography 2.5 mm and 2.5 mm; and stented length 8-18 mm; 23-33 mm; and 33 mm. Quantitative coronary angiographic QCA analysis will be performed at the core lab of the China Cardiovascular Research Foundation for all pre- and post-index procedure angiograms and during the 12-month follow-up period for the pre- and post-reintervention procedures in those cases of clinically-driven PCI revascularization. Also, multivariable analyses will be conducted to investigate potential predictors of 12-month MACE rate in routine clinical practice. 